WO2012040651A3 - Controlled release formulations of opioids - Google Patents

Controlled release formulations of opioids Download PDF

Info

Publication number
WO2012040651A3
WO2012040651A3 PCT/US2011/053132 US2011053132W WO2012040651A3 WO 2012040651 A3 WO2012040651 A3 WO 2012040651A3 US 2011053132 W US2011053132 W US 2011053132W WO 2012040651 A3 WO2012040651 A3 WO 2012040651A3
Authority
WO
WIPO (PCT)
Prior art keywords
controlled release
opioids
release formulations
opioid
methods
Prior art date
Application number
PCT/US2011/053132
Other languages
French (fr)
Other versions
WO2012040651A2 (en
Inventor
Edward M. Rudnic
Michael Vachon
Gary W. Pace
Joseph Berry
Felix De La Iglesia
Original Assignee
QRxPharma Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/024,319 external-priority patent/US20110195989A1/en
Application filed by QRxPharma Ltd. filed Critical QRxPharma Ltd.
Priority to JP2013530379A priority Critical patent/JP2013537915A/en
Priority to CN2011800562785A priority patent/CN103476403A/en
Priority to CA2812570A priority patent/CA2812570A1/en
Priority to AU2011305161A priority patent/AU2011305161A1/en
Priority to EP11764653.9A priority patent/EP2618820A2/en
Publication of WO2012040651A2 publication Critical patent/WO2012040651A2/en
Publication of WO2012040651A3 publication Critical patent/WO2012040651A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Abstract

Pharmaceutical formulations containing opioid components that each has a release profile. The components may provide immediate or controlled release of the opioid. The invention is also directed to methods of controlling release of one or more opioid compounds and methods of treating pain.
PCT/US2011/053132 2010-09-24 2011-09-23 Controlled release formulations of opioids WO2012040651A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2013530379A JP2013537915A (en) 2010-09-24 2011-09-23 Opioid controlled release formulations
CN2011800562785A CN103476403A (en) 2010-09-24 2011-09-23 Controlled release formulations of opioids
CA2812570A CA2812570A1 (en) 2010-09-24 2011-09-23 Controlled release formulations of opioids
AU2011305161A AU2011305161A1 (en) 2010-09-24 2011-09-23 Controlled release formulations of opioids
EP11764653.9A EP2618820A2 (en) 2010-09-24 2011-09-23 Controlled release formulations of opioids

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38622710P 2010-09-24 2010-09-24
US61/386,227 2010-09-24
US13/024,319 2011-02-09
US13/024,319 US20110195989A1 (en) 2010-02-09 2011-02-09 Controlled Release Formulations of Opioids

Publications (2)

Publication Number Publication Date
WO2012040651A2 WO2012040651A2 (en) 2012-03-29
WO2012040651A3 true WO2012040651A3 (en) 2012-05-18

Family

ID=44741728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/053132 WO2012040651A2 (en) 2010-09-24 2011-09-23 Controlled release formulations of opioids

Country Status (6)

Country Link
EP (1) EP2618820A2 (en)
JP (1) JP2013537915A (en)
CN (1) CN103476403A (en)
AU (1) AU2011305161A1 (en)
CA (1) CA2812570A1 (en)
WO (1) WO2012040651A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
CA2687192C (en) 2007-06-04 2015-11-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
AU2013204592A1 (en) * 2012-04-09 2013-10-24 QRxPharma Ltd. Controlled release formulations of opioids
KR20150059167A (en) 2012-07-06 2015-05-29 에갈렛 리미티드 Abuse deterrent pharmaceutical compositions for controlled release
US9707184B2 (en) * 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
CN114515282B (en) * 2020-11-19 2023-09-08 山东大学 Application of Sorbic acid in preparation of anti-coronavirus infection drugs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110195989A1 (en) * 2010-02-09 2011-08-11 Rudnic Edward M Controlled Release Formulations of Opioids

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
UA81224C2 (en) * 2001-05-02 2007-12-25 Euro Celtic S A Dosage form of oxycodone and use thereof
US20030092724A1 (en) * 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
US20030125347A1 (en) * 2001-11-02 2003-07-03 Elan Corporation Plc Pharmaceutical composition
US8906413B2 (en) * 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
AU2005323534A1 (en) 2005-01-05 2006-07-13 Philip S. Portoghese Analgesic conjugates
US20080248110A1 (en) * 2005-03-28 2008-10-09 Anders Pettersson Pharmaceutical Compositions Useful in the Treatment of Pain
US20090082466A1 (en) 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
JP2010509227A (en) * 2006-11-07 2010-03-25 ネクター セラピューティックス エイエル，コーポレイション Opioid agonist and opioid antagonist dosage forms and co-administration
US20090291975A1 (en) * 2008-05-20 2009-11-26 Warren Stern Dual opioid pain therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110195989A1 (en) * 2010-02-09 2011-08-11 Rudnic Edward M Controlled Release Formulations of Opioids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
U.S. Provisional Application Ser. No. 61/302,698 filed Feb. 9, 2010 *

Also Published As

Publication number Publication date
AU2011305161A1 (en) 2013-05-09
JP2013537915A (en) 2013-10-07
WO2012040651A2 (en) 2012-03-29
CA2812570A1 (en) 2012-03-29
EP2618820A2 (en) 2013-07-31
CN103476403A (en) 2013-12-25

Similar Documents

Publication Publication Date Title
WO2012040651A3 (en) Controlled release formulations of opioids
IL207713A0 (en) Formulation and method for the prevention and treatment of bone metastases or other bone diseases
IL225471A0 (en) Compositions and methods for the prevention and treatment of cancer
ZA201202596B (en) Compounds for the treatment of dyslipidemia and related diseases
IL224544B (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
EP2528603A4 (en) Pharmaceutical compositions for the treatment of pain and other indicatons
IL210810A0 (en) Compositions for the treatment of pain and/or inflamtion
HK1215787A1 (en) Pharmaceutical combination for the treatment of pain
IL251083B (en) Compounds and compositions for the treatment of cancer
EP2558085A4 (en) Compositions and methods for the prevention and treatment of cancer
IL211313A0 (en) Compounds, compositions and methods for the treatment of ??-amyloid diseases and synucleinopathies
SG10201405392RA (en) Method of treatment of neurodegenerative or neuro-muscular degenerative diseases andtherapeutic agent to treat the same
IL213703A (en) Compounds for the treatment of pain and other diseases
PL2331092T3 (en) Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
WO2013153451A3 (en) Controlled release formulations of opioids
PL2493305T3 (en) 2-aminoindole compounds and methods for the treatment of malaria
SG10201403562UA (en) Implant for the treatment or prevention of an aneurysm
GB201008792D0 (en) Apparatus for exfoliating skin and/or for the relief of itches
AU2010904906A0 (en) Methods and compositions for the treatment and prevention of skin disorders
AU2010903965A0 (en) Formulation and method for the treatment of timber
IL221238A0 (en) Pharmaceutical compositions and methods for the treatment and prevention of cancer
HU0800083D0 (en) Pharmaceutical compositions for the treatment and prevention of tumorous diseases
EP2276502A4 (en) Compositions for the prevention and treatment of neuroinjury and methods of use thereof
AU2008902119A0 (en) Stimulation system for the treatment of tinnitus
AU2012900286A0 (en) "Methods of treatment or prophylaxis"

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11764653

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013530379

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2812570

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2011764653

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011764653

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011305161

Country of ref document: AU

Date of ref document: 20110923

Kind code of ref document: A